时间：3月19日星期二16:00-17:30

Time：4:00-5:30 PM，Tuesday, March 19，2024

主持人：西湖大学生命科学学院特聘研究员 陈子博

    Host：Dr. Zibo Chen, PI of School of Life Sciences

    地点：云谷校区E9-109会议室

    Venue：Room E9-109, Yungu Campus

主讲嘉宾/Speaker:

Dr. Li Tang, Associate Professor, École Polytechnique Fédérale de Lausanne (EPFL)

Li Tang received his B.S. in Chemistry from Peking University, China, in 2007, and Ph.D. in Materials Science and Engineering from University of Illinois at Urbana-Champaign, USA, in 2012. He was an CRI Irvington Postdoctoral Fellow in the laboratory of Prof. Darrell Irvine at Massachusetts Institute of Technology during 2013-2016. He joined the faculty of Institute of Bioengineering, and Institute of Materials Science & Engineering, at École polytechnique fédérale de Lausanne (EPFL), Switzerland, as a Tenure-Track Assistant Professor in 2016, and promoted to Associate Professor with tenure in 2022. His research focuses on developing multidimensional immunoengineering approaches for enhanced cancer immunotherapies. Dr. Tang is the recipient of Cancer Research Institute CLIP Award (2021), Anna Fuller Award (2021 and 2022), and named in the MIT Technology Review’s "Top 35 Innovators under Age 35" list of China region (2020), Materials Horizons Emerging Investigator (2020), Biomaterials Science Emerging Investigator (2019), and the recipient of European Research Council (ERC) starting grant (2018), and Nano Research Young Innovator Award (NR 45 under 45) (2018).

讲座摘要/Abstract:

Our immune system interacts with many diseases in a multidimensional manner involving substantial biological, chemical, and physical exchanges. Manipulating the disease-immunity interactions may afford novel immunotherapies to better treat diseases such as cancer. In this talk, I will share our recent discovery of IL-10 as a metabolic reprogramming agent that reinvigorates the terminally exhausted CD8+ tumor infiltrating lymphocytes. This strategy has been extended to develop metabolically armored CAR-T cells with IL-10 secretion to counter exhaustion-associated dysfunction in the tumor microenvironment for enhanced anticancer immunity. This new CAR-T cell therapy, i.e. IL-10-secreting CAR-T, has shown promise in several on-going IIT clinical trials (ClinicalTrials.gov ID: NCT05715606, NCT05747157, NCT06120166) in the treatment of refractory/relapsed CD19+ B cell leukemia and lymphoma.

联系人/Contact：

生命科学学院

于文越 yuwenyue@westlake.edu.cn